Appendix Table C3. Survival and local control outcomes of studies that address Key Question 1

| Study | Survival Outcomes for Intervention Group 1 | Survival Outcomes for Intervention Group 2 | Local Control Outcomes for Intervention Group 1 | Local Control Outcomes for Intervention Group 2 | Arm |
| --- | --- | --- | --- | --- | --- |
| Andratschke  2011, #132 | SBRT:  **Overall survival:**  Median 29 months  1-year: 79%  3-years: 38%  5-years: 17%  **Cancer/disease specific**  **survival:**  Median 46 months  1-year: 93%  3-years: 64%  5-years: 48% | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | SBRT  **Local control:**  1-year: 89%  3-years: 83%  5-years: 83% | **Local control:**  NA | No |
| Baumann  2006, #271 | SBRT  **Overall survival:**  3-year: 52%  5-year: 26%  **Cancer/disease specific**  **survival:**  3-year: 66%  5-year: 40% | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | SBRT  **Local control:**  88%  Time to failure: 17.8 (10-49)  months | **Local control:**  NA | No |
| Baumann  2009, #270 | SBRT  **Overall survival:**  Median: 40.6 months  1-year: 68%  2-years:65%  3-years:60%  **Cancer/disease specific**  **survival:**  1-year: 93%  2-years:88%  3-years:88% | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | SBRT  **Local control:**  3-years: 92% | **Local control:**  NA | No |
| Bogart-2010,  #382 | 3DRT  **Overall survival:**  Median: 38.5 months  (95% CI: 22.4 to 58.7)  **Cancer/disease specific**  **survival:**  NR | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | 3DRT  **Local control:**  93% | **Local control:**  NA | No |
| Bollineni-2012,  #4548 | SBRT:  **Overall survival:**  Median NR  2-years high SUV: 62%  2-years low SUV: 81%  **Cancer/disease specific**  **survival:**  Median NR  2-years high SUV: 74%  2-years low SUV: 90% | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | SBRT  **Local control:**  2-years: 96% | **Local control:**  NA | No |
| Bradley-2003,  #445 | 3DRT  **Overall survival:**  1-year: 73%  2-year: 51%  3-year: 34%  **Cancer/disease specific**  **survival:**  1-year: 82%  2-year: 67%  3-year: 51% | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | 3DRT  **Local control:**  1-year: 88%  2-year: 69%  3-year: 63% | **Local control:**  NA | No |
| Burdick-2010,  #521 | SBRT  **Overall survival:**  2-year: 33%  (95% CI: 18%-51%)  **Cancer/disease specific**  **survival:**  NR | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | SBRT  **Local control:**  2-year: 94% | **Local control:**  NA | No |
| Bush-2004,  #535 | PBRT  **Overall survival:**  Total 3-year: 44%  Rx 51 CGE, 3-year: 27%  Rx: 60 CGE, 3-year: 55%  (p=0.03)  **Cancer/disease specific**  **survival:**  3-year: 72% | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | PBRT  **Local control:**  3-year:74% | **Local control:**  NA | No |
| Campeau  2009, #565 | 3DRT  **Overall survival:**  2-year: 61.3%  **Cancer/disease specific survival:**  NR | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | 3DRT  **Local control:**  2-year: 85% | **Local control:**  NA | No |
| Coon-2008,  #803 | SBRT  **Overall survival:**  11 months: 81%  **Cancer/disease specific**  **survival:**  NR | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | SBRT  **Local control:**  11 months: 85% | **Local control:**  NA | No |
| Dunlap-2010,  #1032 | SBRT  **Overall survival:**  Median: 20.1 months (95% CI: 18.7-28.4)  1-year: 85%  2-year:45%  **Cancer/disease specific**  **survival:**  3-year: 82% | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | SBRT  **Local control:**  2-year: 83%  Stage IA, 2-years:90%  Stage IB, 2-years: 70%  (p=0.035) | **Local control:**  NA | No |
| Fritz-2008,  #1238 | SBRT  **Overall survival:**  Median:37 months  2-year: 66%  3-year:53%  **Cancer/disease specific**  **survival:**  2-year:71%  3-year:57% | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | SBRT  **Local control:**  3-year: 81% | **Local control:**  NA | No |
| Graham-2006,  #1403 | 3DRT  **Overall survival:**  Median 43 months  5-years: 30% (95% CI: 13-48%)  **Cancer/disease specific**  **survival:**  5-years: 53% (95% CI: 28-72%) | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | 3DRT  **Local control:**  NA | **Local control:**  NA | No |
| Iwata-2010,  # 1747 | **Overall survival:**  3-years: 65%    **Cancer/disease specific survival:**  NR | **Overall survival:**  NA  **Cancer/disease specific survival:**  NA | **Local control:**  NR | **Local control:**  NA | Yes |
| Jimenez-2010,  #1842 | 3DRT  **Overall survival:**  3-years: 44% (95% CI: 28-58%)  **Cancer/disease specific**  **survival:**  NR | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | 3DRT  **Local control:**  NR | **Local control:**  NA | No |
| Kopek-2009,  #2040 | SBRT  **Overall survival:**  Median 22 months  1-year: 67%  2-years: 49%  3-years: 36%  4-years: 24%  5-years: 21%  **Cancer/disease specific**  **survival:**  Median 61 months | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | SBRT  **Local control:**  4-years: 89% | **Local control:**  NA | No |
| Mirri-2009,  #2576 | 3DRT  **Overall survival:**  1-year: 81%  3-years: 61%  **Cancer/disease specific**  **survival:**  NR | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | 3DRT  **Local control:**  1-year: 88%  3-years: 72% | **Local control:**  NA | No |
| Nakayama  2010,  #2684 | PBRT  **Overall survival:**  2-years: 98% (95% CI, 94-102%)  **Cancer/disease specific**  **survival:**  2-years: 100% | **Overall survival:**  NA  **Cancer/disease specific survival:**  NA | PBRT  **Local control:**  2-years: 97% (95% CI, 91-103%) | **Local control:**  NA | No |
| Narayan-2004,  #2686 | 3DRT  **Overall survival:**  2-years: 54%  3-years: 33%  **Cancer/disease specific**  **survival:**  2-years: 76%  3-years: 48% | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | 3DRT  **Local control:**  77% | **Local control:**  NA | No |
| Nyman-2006,  #2750 | SBRT  **Overall survival:**  Median: 39 months  1-year: 80%  2-years: 71%  3-years: 55%  5-years: 30%  **Cancer/disease specific**  **survival:**  Median: 55 months  1-year: 88%  2-years: 83%  3-years: 67%  5-years: 41% | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | SBRT  **Local control:**  80% | **Local control:**  NA | No |
| Olsen-2011,  #2792 | SBRT  **Overall survival:**  Median overall : 14 months (not  reached)  Median 34 months for each dose  group  **Cancer/disease specific**  **survival:**  NR | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | SBRT  **Local control:**  45 Gy:  1-year: 75%  2-years: 50%  50 Gy:  1-year: 100%  2-years: 100%  54 Gy:  1-year: 99%  2-years: 91% | **Local control:**  NA | No |
| Palma 2012,  #2843 | SBRT  **Overall survival:**  Median: 32 months  1-year: 79%  3-years: 47%  5-years: 28%  **Cancer/disease specific**  **survival:**  NR | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | SBRT  **Local control:**  3-years: 89% | **Local control:**  NA | No |
| Pennathur  2007,  #2896 | RFA  **Overall survival:**  Median not reached  Probability at 1-year: 95%  (95% CI, 85-100%)  Probability at 2-years: 68%  (95% CI, 49-96%)  **Cancer/disease specific**  **survival:**  NR | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | RFA  **Local control:**  58% | **Local control:**  NA |  |
| Pennathur  2009, #2898 | SBRT  **Overall survival:**  Median 26.4 (68% CI, 19.6-not  reached) months  1-year: 81% (68% CI, 73-90%)  **Cancer/disease specific**  **survival:**  NR | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | SBRT  **Local control:**  58% | **Local control:**  NA | No |
| Ricardi-2010,  #3098 | SBRT  **Overall survival:**  Median not reached  2-years: 69%  3-years: 57%  **Cancer/disease specific**  **survival:**  2-years: 79%  3-years: 72% | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | SBRT  **Local control:**  3-years: 88% | **Local control:**  NA | No |
| Scorsetti-2007,  Italy, #3362 | SBRT  **Overall survival:**  1-year: 93±5%  2-years: 53±11%  **Cancer/disease specific**  **survival:**  NR | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | SBRT  **Local control:**  NR | **Local control:**  NA | No |
| Shibamoto 2012, #4629 | SBRT:  **Overall survival:**  Median ~52 months  3-years: 59%  5-years: 44%  **Cancer/disease specific**  **survival:**  NR by operability | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | SBRT  **Local control:**  NR by operabilty | **Local control:**  NA | No |
| Song-2009,  #3549 | SBRT  **Overall survival:**  1-year: 71%  2-years: 38%  **Cancer/disease specific**  **survival:**  NR | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | SBRT  **Local control:**  1-year: 85%  2-years: 85% | **Local control:**  NA | No |
| Stephans  2009, #3614 | SBRT  **Overall survival:**  1-year: 81% (all patients)  1.5-years: 75% (all patients)  1-year: 83% (50 Gy)  1-year: 77% (60 Gy)  **Cancer/disease specific**  **survival:**  NR | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | SBRT  **Local control:**  6-months:100% (all patients)  1-year: 98% (all patients)  1.5-years: 95% (all patients)  1-year: 97% (50 Gy)  1-year: 100% (60 Gy) | **Local control:**  NA | No |
| Taremi-2011,  Canada, #3732 | SBRT  **Overall survival:**  All patients  1-year: 84% (95% CI, 76-90%)  4-years: 30% (95% CI, 15-46%)  **Cancer/disease specific**  **survival:**  All patients  1-year: 92% (95% CI, 87-98%)  4-years: 77% (95% CI, 64-89%) | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | SBRT  **Local control:**  All patients  1-year: 92% (95% CI, 86-97%)  4-years: 89% (95% CI, 81-96%)  Biopsy-proven  1-year: 93% (95% CI, 87-98%)  Nonbiopsy-proven  1-year: 87% (95% CI, 76-99%)  p = 0.41 versus biopsy-proven | **Local control:**  NA | No |
| Takeda-  2009, #3700 | SBRT  **Overall survival:**  3-years: 90% (stage IA)  3-years: 63% (stage IB) p = 0.09  3-years: 77% (inoperable) p = 0.31  **Cancer/disease specific survival:**  3-years: 100% (stage IA)  3-years: 81% (stage IB) p = 0.10  3-years: 94% (inoperable) p = 0.66 | **Overall survival:**  NA  **Cancer/disease specific survival:**  NA | SBRT  **Local control:**  3-years: 93% (stage IA)  3-years: 96% (stage IB) p = 0.86 | **Local control:**  NA | No |
| Turzer-2011,  #3842 | SBRT  **Overall survival:**  97% (calculated)  **Cancer/disease specific**  **survival:**  NR | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | SBRT  **Local control:**  1.5 years: 100% | **Local control:**  NA | No |
| Vahdat-2010,  #3864 | SBRT  **Overall survival:**  2-years: 90%  **Cancer/disease specific**  **survival:**  85% (calculated) | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | SBRT  **Local control:**  2-years: 95% | **Local control:**  NA | No |
| van der Voort  van Zyp-2009,  #3885 | SBRT  **Overall survival:**  1-year: 83% (95% CI, 71-90%)  2-years: 62% (95% CI, 45-75%)  **Cancer/disease specific**  **survival:**  1-year: 94%  2-years: 86% | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | SBRT  **Local control:**  60 Gy  2-years: 78% (95% CI, 84-99%)  45 Gy  2-years: 78% (95% CI, 37-94%) | **Local control:**  NA | No |
| Videtic-2010,  #3958 | SBRT  **Overall survival:**  Median 38 months  3-years: 52%  **Cancer/disease specific**  **survival:**  SBRT  69% (calculated) | **Overall survival:**  NA  **Cancer/disease specific**  **survival:**  NA | SBRT  **Local control:**  3-years: 94% | **Local control:**  NA | No |